Table 2.

Incidence of MYC/BCL2 protein co-expression in diffuse large B-cell lymphoma patients treated with R-CHOP.

Study	Predicts OS/PFS	% double IHC positive	Cut- point for MYC +	Predominantly ABC subtype
Kluk et al. [45]	Yes	Not available	50%	Unspecified
Green et al. [16]	Yes	29%	40%	Yes
Johnson et al. [12]	Yes	21%	40%	Yes
Horn et al. [13]	Yes	26%	40%	Unspecified
Hu et al. [14]	Yes	33%	40%	Yes
Valera et al. [24]	Yes	27%	10%	Unspecified
Perry et al. [46]	Yes	44%	50%	No
Yan et al. [47]	Yes	28%	40%	Yes
Scott et al. [3]	Yes	31%	40%	Yes

Overall survival (OS); Progression free survival (PFS); IHC (immunohistochemistry).